Tarsus Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, announced new data from its Saturn-1 Phase 2b/3 pivotal trial and the Titan real-world collarette prevalence study at the American Society of Cataract and Refractive Surgery 2021 Annual Meeting.
July 24, 2021
· 12 min read